Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.165 USD | -9.69% | +9.91% | +128.43% |
May. 06 | Oppenheimer Upgrades Chemomab Therapeutics to Outperform | MT |
Apr. 10 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 18.34M |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | -21M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-43
x | P/E ratio 2025 * |
-28.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 4.97% |
Latest transcript on Chemomab Therapeutics Ltd.
1 day | -9.69% | ||
1 week | +9.91% | ||
Current month | +8.89% | ||
1 month | +36.61% | ||
3 months | +64.02% | ||
6 months | +140.31% | ||
Current year | +128.43% |
Managers | Title | Age | Since |
---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 11-09-21 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 19-12-31 |
Chief Tech/Sci/R&D Officer | 56 | 22-11-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 20-03-31 |
Nissim Darvish
CHM | Chairman | 59 | 21-03-15 |
Claude Nicaise
BRD | Director/Board Member | 71 | 21-03-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 1.165 | -9.69% | 78 769 |
24-06-05 | 1.29 | +4.03% | 89,400 |
24-06-04 | 1.24 | +1.64% | 97,117 |
24-06-03 | 1.22 | +14.03% | 391,594 |
24-05-31 | 1.07 | +0.93% | 204,436 |
Delayed Quote Nasdaq, June 06, 2024 at 12:02 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+128.43% | 18.34M | |
+18.35% | 125B | |
+14.21% | 109B | |
-2.20% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.48% | 16.64B | |
+0.19% | 13.45B | |
+23.33% | 11.32B |
- Stock Market
- Equities
- CMMB Stock